Abstract:What is known and Objective: Cytochrome P450 2C19 (CYP2C19) and CYP2D6 are important xenobiotic metabolic enzymes and both show considerable genetic variability between Orientals and Caucasians. There are known marked heterogeneity in susceptibility to various cancers and hypertension among Chinese Mongolian, Hui and Han ethnic groups, but the molecular mechanisms are unknown. Our objective was to investigate the patterns of distribution of CYP2C19 and CYP2D6 polymorphisms among healthy Chinese subjects to determine whether any observed inter-ethnic variability might be worth further investigation as possible contributors to the known differences in disease prevalence. Methods: Blood samples were collected from 454 unrelated Chinese healthy subjects (214 Han, 111 Hui, 129 Mongolian) for genotyping analysis. The single nucleotide polymorphisms (SNPs) CYP2C19*2 (681G>A in exon 5), CYP2C19*3 (636G>A in exon 4) and CYP2D6*10 (188C>T in exon 1) were determined by the polymerase chain reactionrestriction fragment length polymorphism (PCR-RFLP) method. Results and Discussion: Significantly higher frequencies of the CYP2C19 poor metabolic genotypes were observed in Chinese Han (18.7%), Chinese Hui (25.0%) and Chinese Mongolian (10.9%) subjects than has been reported for Caucasians (1.73.0%, P < 0.01). The prevalent defective allele CYP2C19*2 occurred more frequently in both Chinese Hui (32.4%) and Han (29.7%) than in Chinese Mongolian (18.2%, P < 0.01) subjects. The CYP2C19*2 and CYP2C19*3 defective alleles were significantly more frequent in Chinese Han and Chinese Hui ethnic groups than have been reported for Caucasians (11.116.3% and 00.2%, P < 0.01). CYP2D6*1/*10 heterozygotes and CYP2D6*10/*10 homozygotes were observed more frequently in Chinese Han (43.1% and 27.2%), Hui (40.6% and 30.7%) and Mongolian subjects (31.3% and 9.6%, both P < 0.01) than have been reported for Caucasians (5.5% and 0.3%, P < 0.01). In Chinese Mongolians, the CYP2D6*10 allele occurred at a frequency (25.2%, P < 0.01) intermediate between those reported for Caucasians and the other two Chinese ethnic populations. What is new and Conclusions: This is first report of interethnic differences in frequencies of functional CYP2C19 and CYP2D6 genes among Chinese Mongolian, Hui and Han populations. These differences may be important in explaining reported inter-ethnic differences in disease prevalence and response to drugs.

Effect of Cyp1a2 Polymorphism on the Pharmacokinetics of Agomelatine in Chinese Healthy Male Volunteers

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Inter- And Intra-Individual Variability In The Pharmacokinetics Of Agomelatine Tablets In Chinese Healthy Male Subjects

Bioequivalence and Pharmacokinetic Profiles of Agomelatine 25-Mg Tablets in Healthy Chinese Subjects: A Four-Way Replicate Crossover Study Demonstrating High Intra- and Inter-Individual Variations

A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers

Evaluation Of The Highly Variable Agomelatine Pharmacokinetics In Chinese Healthy Subjects To Support Bioequivalence Study

The G-113a Polymorphism In Cyp1a2 Affects The Caffeine Metabolic Ratio In A Chinese Population

Influence of CYP2D6 Genetic Polymorphism on Pharmacokinetics of Paroxetine in Chinese Healthy People

Genetic polymorphism analysis of the drug-metabolizing enzyme CYP1A2 in a Uyghur Chinese population: a pilot study.

Differences in Genotype and Allele Frequency Distributions of Polymorphic Drug Metabolizing Enzymes CYP2C19 and CYP2D6 in Mainland Chinese Mongolian, Hui and Han Populations

Atomoxetine Pharmacokinetics in Healthy Chinese Subjects and Effect of the CYP2D6*10 Allele.

Pharmacokinetics of Citalopram in Relation to Genetic Polymorphism of CYP2C19.

Influence of CYP2D6 Gene Polymorphisms on the Pharmacokinetics of Aripiprazole in Healthy Chinese Subjects.

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers.

Association Study of Multidrug Resistance 1 Gene Polymorphisms with Efficacy and Adverse Drug Reaction of Paroxetine in Major Depressive Patients

The Influence of MDR1 G2677T/A Genetic Polymorphisms on the Pharmacokinetics of Repaglinide in Healthy Chinese Volunteers

Effect of Cyp2d6 Genetic Polymorphism on the Metabolism of Citalopram in Vitro

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects.

[Polymorphisms of Drug-Metabolizing Enzymes Genes in a Han Chinese Population].

Relationship between polymorphism of CYP2C19 gene and changes of liver function induced by antidepressants